©2024 Stanford Medicine
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Not Recruiting
Trial ID: NCT03397394
Purpose
The purpose of the ATLAS study is to determine how patients with locally advanced
unresectable or metastatic urothelial carcinoma respond to treatment with rucaparib.
Official Title
A Phase 2, Open-label Study of Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Stanford Investigator(s)
Sandy Srinivas
Professor of Medicine (Oncology) and, by courtesy, of Urology
Eligibility
Inclusion Criteria:
- Have histologically or cytologically confirmed locally advanced unresectable or
metastatic transitional cell carcinoma of the urothelium (renal pelvis, ureter,
urinary bladder or urethra)
- Received 1 or 2 prior treatment regimens for advanced or metastatic disease
- Confirmed radiologic disease progression during or following recent treatment
- Mandatory biopsy is required during screening
- Measurable disease per RECIST v1.1
- Adequate organ function
- ECOG 0 or 1
Exclusion Criteria:
- Prior treatment with a PARP inhibitor
- Symptomatic and/or untreated CNS metastases
- Duodenal stent and/or any gastrointestinal disorder that may interfere with absorption
of rucaparib
Intervention(s):
drug: Rucaparib
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061